Cartesian Therapeutics, Inc. (RNAC) Total liabilities 2016–2025
Cartesian Therapeutics, Inc. (RNAC) total liabilities at each fiscal year-end, per SEC filings.
$422.7MFY2025 · since FY2016: $34.3M → $422.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $422.7M | -4.3% |
| FY2024 | $441.8M | -0.6% |
| FY2023 | $444.7M | +517.1% |
| FY2022 | $72.1M | -47.5% |
| FY2021 | $137.4M | -25.1% |
| FY2020 | $183.4M | +101.2% |
| FY2019 | $91.2M | +82.7% |
| FY2018 | $49.9M | +1.2% |
| FY2017 | $49.3M | +43.5% |
| FY2016 | $34.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice